Skip to Main Content

Author Details

Vera J Suman
Mayo Clinic
1992
253
67
PMIDPaper TitleJournal TitlePublished Year
36892847Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.JAMA Oncol2023
37226243Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.Breast Cancer Res2023
36653664Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.Ann Surg Oncol2023
36745260ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer.Ann Surg Oncol2023
34671883Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?Ann Surg Oncol2022
35653124Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).Clin Cancer Res2022
35734391Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.NAR Cancer2022
35503516A review of the current status of lenalidomide maintenance therapy in multiple myeloma in 2022.Expert Rev Anticancer Ther2022
34855208Evaluating educational interventions to increase breast density awareness among Latinas: A randomized trial in a Federally Qualified Health Center.Cancer2022
35177654Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer.NPJ Breast Cancer2022
35033304Breast Density Knowledge and Awareness Among Latinas in a Low-Resource Setting.J Am Coll Radiol2022
33981951Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance).JNCI Cancer Spectr2021
33766079Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study.Breast Cancer Res2021
34559902A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202).Am J Hematol2021
34078650Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).Clin Cancer Res2021
34101624FOXA1 overexpression suppresses interferon signaling and immune response in cancer.J Clin Invest2021
34073689Future Directions in Maintenance Therapy in Multiple Myeloma.J Clin Med2021
32538690An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.Thyroid2020
31809326Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma: Results of a Study of Academic and Community Cancer Research United (ACCRU) RU261206I.Am J Clin Oncol2020
31665365Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).J Natl Cancer Inst2020
32098767Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.Clin Cancer Res2020
32589921Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.Biol Blood Marrow Transplant2020
32699021A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel Lymph node Endometrial Cancer Trial).Int J Gynecol Cancer2020
32325171Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.Biol Blood Marrow Transplant2020
32430040Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.Breast Cancer Res2020
30635635Commentary on "Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma" by Giovanni Barosi and Robert Peter Gale.Leukemia2019
31832106The emerging role of CDK4/6i in HER2-positive breast cancer.Ther Adv Med Oncol2019
31852492Behavioral and psychological impact of returning breast density results to Latinas: study protocol for a randomized clinical trial.Trials2019
30193295Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.JAMA Oncol2019
29884841Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models.Genet Med2019
31211604Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM.J Clin Oncol2019
31231469Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.Oncotarget2019
31166752Comparison of <sup>99m</sup>Tc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy.AJR Am J Roentgenol2019
30661162Should Overall Survival Remain an Endpoint for Multiple Myeloma Trials?Curr Hematol Malig Rep2019
29289986Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Breast Cancer Res Treat2018
30100988Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.Oncotarget2018
30013765Update on the role of lenalidomide in patients with multiple myeloma.Ther Adv Hematol2018
30114337Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.J Surg Oncol2018
30089255Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.Cell Rep2018
30257941ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.Proc Natl Acad Sci U S A2018
30652605PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient.JCO Clin Cancer Inform2018
29666297Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).Oncologist2018
29708513DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.J Clin Invest2018
29365023Comparison of a Medical-Grade Monitor vs Commercial Off-the-Shelf Display for Mitotic Figure Enumeration and Small Object (Helicobacter pylori) Detection.Am J Clin Pathol2018
27866278Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).Breast Cancer Res Treat2017
28453704Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.Ann Oncol2017
28376176Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.J Natl Cancer Inst2017
29207686Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.Oncotarget2017
29228549ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer.Oncotarget2017
29029287Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer.J Clin Endocrinol Metab2017
  • 1 - 50 of 253

Recommended Authors

Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 4
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 15
Clinical Investigations Branch, National Cancer Institute
Career Start Year 2004
Number of shared co-authors 15
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 2
University of Virginia
Career Start Year 2002
Number of shared co-authors 2
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 8
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 3
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 4
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 2
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 5
Memorial Sloan Kettering Cancer Center
Career Start Year 1996
Number of shared co-authors 6
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1993
Number of shared co-authors 0
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 5
Robert H Lurie Comprehensive Cancer Center of Northwestern University
Career Start Year 1991
Number of shared co-authors 1
Warwick Clinical Trials Unit, University of Warwick
Career Start Year 1991
Number of shared co-authors 8
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 10
GZA Ziekenhuizen Campus Sint-Augustinus, University of Antwerp
Career Start Year 1988
Number of shared co-authors 3
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
St Jude Children's Research Hospital.
Career Start Year 1988
Number of shared co-authors 4
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 1986
Number of shared co-authors 11
Westmead Clinical School, University of Sydney
Career Start Year 1986
Number of shared co-authors 9
Harvard Medical School
Career Start Year 1985
Number of shared co-authors 5
University of Bern
Career Start Year 1985
Number of shared co-authors 2
Walter Reed National Military Medical Center
Career Start Year 1985
Number of shared co-authors 1
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 4
UCL Great Ormond Street Institute of Child Health, University College London
Career Start Year 1976
Number of shared co-authors 17
Memorial Sloan Kettering Cancer Center
Career Start Year 1976
Number of shared co-authors 17
NYU Grossman School of Medicine
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Mayo Clinic
Co-authored papers 70
Mayo Clinic
Co-authored papers 44
Mayo Clinic
Co-authored papers 24
Mayo Clinic
Co-authored papers 22
Co-authored papers 19
Mayo Clinic
Co-authored papers 16
The University of Texas MD Anderson Cancer Center
Co-authored papers 15
Mayo Clinic
Co-authored papers 10
Co-authored papers 10
Mayo Clinic
Co-authored papers 10
Co-authored papers 9
Mayo Clinic
Co-authored papers 8
Co-authored papers 8
Mayo Clinic
Co-authored papers 8
Mayo Clinic School of Medicine, Mayo Clinic
Co-authored papers 8
Mayo Clinic Jacksonville
Co-authored papers 8
Mayo Clinic
Co-authored papers 8
Mayo Clinic
Co-authored papers 7
Division of Biostatistics and Clinical Trials, Mayo Clinic
Co-authored papers 7
Washington University School of Medicine
Co-authored papers 6
Inova Health System
Co-authored papers 6
Mayo Clinic
Co-authored papers 5
Dana-Farber Cancer Institute
Co-authored papers 5
University of Texas MD Anderson Cancer Center
Co-authored papers 5
Mayo Clinic
Co-authored papers 5
Mayo Clinic
Co-authored papers 5
University of California san francisco
Co-authored papers 4
Mayo Clinic
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4